Quantoom Biosciences
Time 2022-09-12 02:28:44Web Name: Quantoom Biosciences
WebSite: http://www.quantoom.com
ID:312469
Keywords:
Quantoom,BiosciencesDescription:
Quantoom Biosciences
Greater access and autonomy through innovation in bioproduction
We are on a mission to remove the barriers to making mRNA-based vaccines & therapeutics,
at every stage from sequence up to mass production.
Who We Are
Quantoom Biosciences, a Univercells company, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production.
We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology.
In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering.
Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem.
Who We Are
Quantoom Biosciences, a Univercells company, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production.
We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology.
In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering.
Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem.
what we do
At Quantoom Biosciences, we are bringing radical innovation to the way mRNA is produced in any research lab, biotech biopharma and CDMO. We support our partners early on with sequence design & candidate screening up to (pre-)clinical development toward a successful mRNA product.
Our technologies are based on our Intensification and chaining engineering principles that deliver small footprint, automated and cost-effective bioproduction technologies.
More specifically, we have developed:
what we do
At Quantoom Biosciences, we are bringing radical innovation to the way mRNA is produced in any research lab, biotech biopharma and CDMO. We support our partners early on with sequence design & candidate screening up to (pre-)clinical development toward a successful mRNA product.
Our technologies are based on our Intensification and chaining engineering principles that deliver small footprint, automated and cost-effective bioproduction technologies.
More specifically, we have developed:
Our GMP-grade RNA Production System
We designed our RNA Production System with end users’ needs in mind, creating a radically different manufacturing technology with two features at its core.
These features deliver a set of benefits for mRNA drug developers;
1No scale-up needed (pre-)clinical development is already at the final scale, which accelerates your process & product development
2Single small footprint system that integrates all process steps - no need to invest in a suite of equipment
3Generic process that is adaptable to your specific RNA construct both for transcription and purification, with polishing options
4Reduced CoGs thanks to minimal labor & RNA expertise required
5In vivo validated with multiple RNA constructs to de-risk your product development
Key numbers:Up to 20 g per day (5 kg per year) of purified mRNA per system
Up to 100 million doses (50 µg) per year
Our GMP-grade RNA Production System
We designed our RNA Production System with end users’ needs in mind, creating a radically different manufacturing technology with two features at its core.
These features deliver a set of benefits for mRNA drug developers;
1No scale-up needed (pre-)clinical development is already at the final scale, which accelerates your process & product development
2Single small footprint system that integrates all process steps - no need to invest in a suite of equipment
3Generic process that is adaptable to your specific RNA construct both for transcription and purification, with polishing options
4Reduced CoGs thanks to minimal labor & RNA expertise required
5In vivo validated with multiple RNA constructs to de-risk your product development
Key numbers:Up to 20 g per day (5 kg per year) of purified mRNA per systemUp to 100 million doses (50 µg) per yearWhat we can help you with today
1RNA Research, Development & Production from sequence to clinical batch production
2Early adopter partner agreement for our RNA Production System offering preferential conditions & services
3Strategic collaboration to accelerate mutual interests
What makes us different
We deliver access and autonomy through innovation
innovation - Disruptive innovation as the driver of everything we doAccess - Lower entry barriers to drug development and productionAutonomy - Self-sufficient production up to commercial scaleWhat makes us different
We deliver access and autonomy through innovation
innovation - Disruptive innovation as the driver of everything we doAccess - Lower entry barriers to drug development and productionAutonomy - Self-sufficient production up to commercial scaleEnabling more organisations to explore a wider range of
product development opportunities to get to treatments faster.
Enabling more organisations to explore a wider range of product development opportunities to get to treatments faster.
Our Team
Our team consists of international experts whose talent, experience and commitment
make the company a key player in therapeutic development and biomanufacturing.
Management Team
José Castillo
Chief Executive Officer
(and Univercells Co-Founder)
Kristof Vandekerckhove
Chief Scientific Officer & Head of Research BE
Yves Ghislain
Head of Technical Development & Operations
Conor Cahill
Head of Product Development
Irina Gbalou
Head of Research FR
Guillaume Roelandts
Head of Commercial Operations
Rachana Talwar
Head of PMO & Chief of Staff
Strategic & Scientific Advisory Board
NEws & views
Press Releases
New agreement paves way for development of first African-owned COVID-19 vaccine
Read MoreUnivercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis
Read MoreQuantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics
Read MoreeTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System
Read MoreRelevant resources
Careers
Quantoom biosciences is always looking for talented people to join the team!
Discover our open positions or submit a speculative application.
Contact Us
Quantoom’s headquarters
Quantoom France
All Right Reserved
Quantoom Biosciences 2022Cookies Policies | Privacy Policy | All Right Reserved – Quantoom Biosciences 2022
TAGS:Quantoom Biosciences
<<< Thank you for your visit >>>
Websites to related : TwinStrand Biosciences - An end-
Technology Applications AML MRD
D-Mark Biosciences keywords:
description:Trusted Advisor and Premier Provider for Advanced Genomics Solutions to Molecular Biology and Protein Biology laboratories. The
keywords:
description:
HOMEPRODUCTSTECHNICAL RESOURCESNEWSABOUT USCONTACT US
keywords:
description:The PhD program in Cellular & Molecular Biosciences at UC Irvine provides ideal training to launch the careers of talented resea
keywords:
description:Biosciences at the University of Exeter is a rapidly expanding international centre with researchers working at the cutting edge
Her türlü yerli yabancı pornoyu bulabileceğiniz türkiyenin en büyük sex adresi. porno , eğer bununlada tahmin olmuyorsanız diğer bir site ol
Welcome to Medkoo BiosciencesMedKoo (doing business as MedKoo Biosciences) is a global leading biochemical reagent supplier, specializing in lab-use small molecule drugs. We make,
Nutrition BiosciencesResearch Shows the Impact of Litesse® Fiber on Gut Microbiota and Lipid Metabolism in Mice Discover More We apply our knowledge of our customers and
BioTek, ACEA Biosciences, and AgACEA Biosciences in Now Agilent ACEA Biosciences officially joined the Agilent family September 1st, 2020. We are committed to providing flow cytometr
Welcome to anjibiosciencesAnji Biosciences was established by an experienced team of doctorates in 2007 and specializes in the synthesis and supply of high-quality organic fine
adsHot Websites